These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38250850)

  • 1. Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5.
    Wang Z; Zhang B; Ou L; Qiu Q; Wang L; Bylund T; Kong WP; Shi W; Tsybovsky Y; Wu L; Zhou Q; Chaudhary R; Choe M; Dickey TH; El Anbari M; Olia AS; Rawi R; Teng IT; Wang D; Wang S; Tolia NH; Zhou T; Kwong PD
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern.
    Khaleeq S; Sengupta N; Kumar S; Patel UR; Rajmani RS; Reddy P; Pandey S; Singh R; Dutta S; Ringe RP; Varadarajan R
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
    Jangra S; Ye C; Rathnasinghe R; Stadlbauer D; ; Krammer F; Simon V; Martinez-Sobrido L; García-Sastre A; Schotsaert M
    medRxiv; 2021 Jan; ():. PubMed ID: 33532796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
    Walls AC; Miranda MC; Schäfer A; Pham MN; Greaney A; Arunachalam PS; Navarro MJ; Tortorici MA; Rogers K; O'Connor MA; Shirreff L; Ferrell DE; Bowen J; Brunette N; Kepl E; Zepeda SK; Starr T; Hsieh CL; Fiala B; Wrenn S; Pettie D; Sydeman C; Sprouse KR; Johnson M; Blackstone A; Ravichandran R; Ogohara C; Carter L; Tilles SW; Rappuoli R; Leist SR; Martinez DR; Clark M; Tisch R; O'Hagan DT; Van Der Most R; Van Voorhis WC; Corti D; McLellan JS; Kleanthous H; Sheahan TP; Smith KD; Fuller DH; Villinger F; Bloom J; Pulendran B; Baric RS; King NP; Veesler D
    Cell; 2021 Oct; 184(21):5432-5447.e16. PubMed ID: 34619077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines.
    Dickey TH; Ma R; Orr-Gonzalez S; Ouahes T; Patel P; McAleese H; Butler B; Eudy E; Eaton B; Murphy M; Kwan JL; Salinas ND; Holbrook MR; Lambert LE; Tolia NH
    Cell Rep; 2023 Mar; 42(3):112266. PubMed ID: 36943870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    bioRxiv; 2021 Apr; ():. PubMed ID: 32995773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    Sci Adv; 2021 Mar; 7(12):. PubMed ID: 33741598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.
    Mittal N; Kumar S; Rajmani RS; Singh R; Lemoine C; Jakob V; Bj S; Jagannath N; Bhat M; Chakraborty D; Pandey S; Jory A; Sa SS; Kleanthous H; Dubois P; Ringe RP; Varadarajan R
    NPJ Vaccines; 2023 Oct; 8(1):161. PubMed ID: 37880298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
    Cohen AA; Gnanapragasam PNP; Lee YE; Hoffman PR; Ou S; Kakutani LM; Keeffe JR; Wu HJ; Howarth M; West AP; Barnes CO; Nussenzweig MC; Bjorkman PJ
    Science; 2021 Feb; 371(6530):735-741. PubMed ID: 33436524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
    Joyce MG; Chen WH; Sankhala RS; Hajduczki A; Thomas PV; Choe M; Martinez EJ; Chang WC; Peterson CE; Morrison EB; Smith C; Chen RE; Ahmed A; Wieczorek L; Anderson A; Case JB; Li Y; Oertel T; Rosado L; Ganesh A; Whalen C; Carmen JM; Mendez-Rivera L; Karch CP; Gohain N; Villar Z; McCurdy D; Beck Z; Kim J; Shrivastava S; Jobe O; Dussupt V; Molnar S; Tran U; Kannadka CB; Soman S; Kuklis C; Zemil M; Khanh H; Wu W; Cole MA; Duso DK; Kummer LW; Lang TJ; Muncil SE; Currier JR; Krebs SJ; Polonis VR; Rajan S; McTamney PM; Esser MT; Reiley WW; Rolland M; de Val N; Diamond MS; Gromowski GD; Matyas GR; Rao M; Michael NL; Modjarrad K
    Cell Rep; 2021 Dec; 37(12):110143. PubMed ID: 34919799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
    Walls AC; Miranda MC; Pham MN; Schäfer A; Greaney A; Arunachalam PS; Navarro MJ; Tortorici MA; Rogers K; O'Connor MA; Shireff L; Ferrell DE; Brunette N; Kepl E; Bowen J; Zepeda SK; Starr T; Hsieh CL; Fiala B; Wrenn S; Pettie D; Sydeman C; Johnson M; Blackstone A; Ravichandran R; Ogohara C; Carter L; Tilles SW; Rappuoli R; O'Hagan DT; Van Der Most R; Van Voorhis WC; McLellan JS; Kleanthous H; Sheahan TP; Fuller DH; Villinger F; Bloom J; Pulendran B; Baric R; King N; Veesler D
    bioRxiv; 2021 Mar; ():. PubMed ID: 33758839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
    Logue J; Johnson RM; Patel N; Zhou B; Maciejewski S; Foreman B; Zhou H; Portnoff AD; Tian JH; Rehman A; McGrath ME; Haupt RE; Weston SM; Baracco L; Hammond H; Guebre-Xabier M; Dillen C; Madhangi M; Greene AM; Massare MJ; Glenn GM; Smith G; Frieman MB
    Nat Commun; 2023 Feb; 14(1):1130. PubMed ID: 36854666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern.
    Ahmed S; Khan MS; Gayathri S; Singh R; Kumar S; Patel UR; Malladi SK; Rajmani RS; van Vuren PJ; Riddell S; Goldie S; Girish N; Reddy P; Upadhyaya A; Pandey S; Siddiqui S; Tyagi A; Jha S; Pandey R; Khatun O; Narayan R; Tripathi S; McAuley AJ; Singanallur NB; Vasan SS; Ringe RP; Varadarajan R
    Front Immunol; 2021; 12():765211. PubMed ID: 34956193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
    Cohen AA; Gnanapragasam PNP; Lee YE; Hoffman PR; Ou S; Kakutani LM; Keeffe JR; Wu HJ; Howarth M; West AP; Barnes CO; Nussenzweig MC; Bjorkman PJ
    bioRxiv; 2021 Jan; ():. PubMed ID: 33236016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.
    Olivera-Ugarte SM; Bolduc M; Laliberté-Gagné MÈ; Blanchette LJ; Garneau C; Fillion M; Savard P; Dubuc I; Flamand L; Farnòs O; Xu X; Kamen A; Gilbert M; Rabezanahary H; Scarrone M; Couture C; Baz M; Leclerc D
    Nanomedicine; 2022 Aug; 44():102584. PubMed ID: 35850421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.